K243922 is an FDA 510(k) clearance for the Revogene. Classified as Real Time Nucleic Acid Amplification System (product code OOI), Class II - Special Controls.
Submitted by Meridian Bioscience, Inc. (Cincinnati, US). The FDA issued a Cleared decision on March 20, 2025 after a review of 90 days - within the typical 510(k) review window.
This device falls under the Microbiology FDA review panel, regulated under 21 CFR 862.2570 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.
View all Meridian Bioscience, Inc. devices